Global Checkpoint Inhibitors for Treating Cancer Market Growth 2019-2024

Published On: Mar 2019

Format: PDF

Publisher: LP infomation

Pages: 139

Report ID: 237492

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.

According to this study, over the next five years the Checkpoint Inhibitors for Treating Cancer market will register a 28.0% CAGR in terms of revenue, the global market size will reach US$ 20600 million by 2024, from US$ 4690 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Checkpoint Inhibitors for Treating Cancer business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions and countries.

This study considers the Checkpoint Inhibitors for Treating Cancer value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Melanoma Treatment
Bladder Cancer Treatment
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol-Myers Squibb(BMS)
Merck
Roche
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Checkpoint Inhibitors for Treating Cancer consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Checkpoint Inhibitors for Treating Cancer market by identifying its various subsegments.
Focuses on the key global Checkpoint Inhibitors for Treating Cancer manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Checkpoint Inhibitors for Treating Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Checkpoint Inhibitors for Treating Cancer submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2019-2024 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Consumption 2014-2024
2.1.2 Checkpoint Inhibitors for Treating Cancer Consumption CAGR by Region
2.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.2.3 CTLA-4 Inhibitors
2.3 Checkpoint Inhibitors for Treating Cancer Consumption by Type
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2014-2019)
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2014-2019)
2.3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2014-2019)
2.4 Checkpoint Inhibitors for Treating Cancer Segment by Application
2.4.1 Melanoma Treatment
2.4.2 Bladder Cancer Treatment
2.4.3 Other
2.5 Checkpoint Inhibitors for Treating Cancer Consumption by Application
2.5.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2014-2019)
2.5.2 Global Checkpoint Inhibitors for Treating Cancer Value and Market Share by Application (2014-2019)
2.5.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2014-2019)

3 Global Checkpoint Inhibitors for Treating Cancer by Players
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Players (2017-2019)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players (2017-2019)
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Players (2017-2019)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players (2017-2019)
3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Players
3.4 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Checkpoint Inhibitors for Treating Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Checkpoint Inhibitors for Treating Cancer by Regions
4.1 Checkpoint Inhibitors for Treating Cancer by Regions
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Consumption by Regions
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Value by Regions
4.2 Americas Checkpoint Inhibitors for Treating Cancer Consumption Growth
4.3 APAC Checkpoint Inhibitors for Treating Cancer Consumption Growth
4.4 Europe Checkpoint Inhibitors for Treating Cancer Consumption Growth
4.5 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Growth

5 Americas
5.1 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Countries
5.1.1 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2014-2019)
5.1.2 Americas Checkpoint Inhibitors for Treating Cancer Value by Countries (2014-2019)
5.2 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Type
5.3 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Countries
6.1.1 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2014-2019)
6.1.2 APAC Checkpoint Inhibitors for Treating Cancer Value by Countries (2014-2019)
6.2 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Type
6.3 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Countries
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2014-2019)
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Value by Countries (2014-2019)
7.2 Europe Checkpoint Inhibitors for Treating Cancer Consumption by Type
7.3 Europe Checkpoint Inhibitors for Treating Cancer Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer by Countries
8.1.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2014-2019)
8.1.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value by Countries (2014-2019)
8.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Type
8.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Checkpoint Inhibitors for Treating Cancer Distributors
10.3 Checkpoint Inhibitors for Treating Cancer Customer

11 Global Checkpoint Inhibitors for Treating Cancer Market Forecast
11.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2019-2024)
11.2 Global Checkpoint Inhibitors for Treating Cancer Forecast by Regions
11.2.1 Global Checkpoint Inhibitors for Treating Cancer Forecast by Regions (2019-2024)
11.2.2 Global Checkpoint Inhibitors for Treating Cancer Value Forecast by Regions (2019-2024)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Checkpoint Inhibitors for Treating Cancer Forecast by Type
11.8 Global Checkpoint Inhibitors for Treating Cancer Forecast by Application

12 Key Players Analysis
12.1 Bristol-Myers Squibb(BMS)
12.1.1 Company Details
12.1.2 Checkpoint Inhibitors for Treating Cancer Product Offered
12.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2017-2019)
12.1.4 Main Business Overview
12.1.5 Bristol-Myers Squibb(BMS) News
12.2 Merck
12.2.1 Company Details
12.2.2 Checkpoint Inhibitors for Treating Cancer Product Offered
12.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2017-2019)
12.2.4 Main Business Overview
12.2.5 Merck News
12.3 Roche
12.3.1 Company Details
12.3.2 Checkpoint Inhibitors for Treating Cancer Product Offered
12.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2017-2019)
12.3.4 Main Business Overview
12.3.5 Roche News
...

13 Research Findings and Conclusion